Bulletin
Investor Alert

Horizon Therapeutics PLC

NAS: HZNP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 4:09 p.m.

/zigman2/quotes/206690250/composite

$

91.34

Change

0.00 0.00%

Volume

Volume 27,402

Quotes are delayed by 20 min

/zigman2/quotes/206690250/composite

Previous close

$ 87.35

$ 91.34

Change

+3.99 +4.57%

Day low

Day high

$86.66

$91.39

Open

52 week low

52 week high

$70.35

$120.54

Open

Company Description

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, ...

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Valuation

P/E Current

48.25

P/E Ratio (with extraordinary items)

37.39

P/E Ratio (without extraordinary items)

40.41

Price to Sales Ratio

7.16

Price to Book Ratio

4.02

Price to Cash Flow Ratio

28.34

Enterprise Value to EBITDA

23.02

Enterprise Value to Sales

6.35

Total Debt to Enterprise Value

0.07

Efficiency

Revenue/Employee

1,577,368.00

Income Per Employee

279,424.00

Receivables Turnover

4.12

Total Asset Turnover

0.42

Liquidity

Current Ratio

3.45

Quick Ratio

3.36

Cash Ratio

2.38

Profitability

Gross Margin

75.79

Operating Margin

24.37

Pretax Margin

18.25

Net Margin

17.71

Return on Assets

7.42

Return on Equity

12.55

Return on Total Capital

12.38

Return on Invested Capital

9.01

Capital Structure

Total Debt to Total Equity

26.10

Total Debt to Total Capital

20.70

Total Debt to Total Assets

17.30

Long-Term Debt to Equity

26.00

Long-Term Debt to Total Capital

20.62

Officers and Executives

Name Age Officer Since Title
Mr. Timothy P. Walbert 53 2008 Chairman, President & Chief Executive Officer
Mr. Paul W. Hoelscher 55 2014 Chief Financial Officer & Executive Vice President
Dr. Karin Rosen - 2020 Chief Scientific Officer
Dr. Elizabeth H.Z. Thompson - 2018 Executive Vice President-Research & Development
Dr. Jeffrey W. Sherman 65 2009 Chief Medical Officer & Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/21/2022 Timothy P. Walbert
Chairman, President and CEO; Director
9,009   Derivative/Non-derivative trans. at $86.42 per share. 778,557
01/21/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
2,372   Derivative/Non-derivative trans. at $86.42 per share. 204,988
01/21/2022 Paul W. Hoelscher
EVP, CFO
2,463   Derivative/Non-derivative trans. at $86.42 per share. 212,852
01/21/2022 Michael A. DesJardin
EVP, Technical Operations
1,825   Derivative/Non-derivative trans. at $86.42 per share. 157,716
01/21/2022 Timothy P. Walbert
Chairman, President and CEO; Director
20,336   Derivative/Non-derivative trans. at $0 per share. 0
01/21/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
5,354   Derivative/Non-derivative trans. at $0 per share. 0
01/21/2022 Paul W. Hoelscher
EVP, CFO
5,558   Derivative/Non-derivative trans. at $0 per share. 0
01/21/2022 Michael A. DesJardin
EVP, Technical Operations
3,679   Derivative/Non-derivative trans. at $0 per share. 0
01/14/2022 Timothy P. Walbert
Chairman, President and CEO; Director
25,000   Disposition at $90.02 per share. 2,250,500
01/14/2022 Timothy P. Walbert
Chairman, President and CEO; Director
25,000   Derivative/Non-derivative trans. at $22.14 per share. 553,500
01/06/2022 Andy Pasternak
EVP and Chief Business Officer
349   Disposition at $100.23 per share. 34,980
01/06/2022 Andy Pasternak
EVP and Chief Business Officer
6,438   Disposition at $99.85 per share. 642,834
01/06/2022 Andy Pasternak
EVP and Chief Business Officer
700   Disposition at $98.33 per share. 68,831
01/06/2022 Andy Pasternak
EVP and Chief Business Officer
500   Disposition at $97.3 per share. 48,650
01/05/2022 Timothy P. Walbert
Chairman, President and CEO; Director
3,636   Derivative/Non-derivative trans. at $101.84 per share. 370,290
01/05/2022 Timothy P. Walbert
Chairman, President and CEO; Director
174,906   Derivative/Non-derivative trans. at $101.84 per share. 17,812,427
01/05/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
37,675   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Paul W. Hoelscher
EVP, CFO
50,666   Derivative/Non-derivative trans. at $101.84 per share. 5,159,825
01/05/2022 Barry J. Moze
EVP, Chief Admin. Officer
49,841   Derivative/Non-derivative trans. at $101.84 per share. 5,075,807
01/05/2022 Michael A. DesJardin
EVP, Technical Operations
41,276   Derivative/Non-derivative trans. at $101.84 per share. 4,203,547
01/05/2022 Miles W. McHugh
Sr VP & Princ. Acctg Officer
8,175   Derivative/Non-derivative trans. at $101.84 per share. 832,542
01/05/2022 Andy Pasternak
EVP and Chief Business Officer
21,710   Derivative/Non-derivative trans. at $101.84 per share. 2,210,946
01/05/2022 Elizabeth H.Z. Thompson
EVP, Research & Development
7,030   Derivative/Non-derivative trans. at $101.84 per share. 715,935
01/05/2022 Timothy P. Walbert
Chairman, President and CEO; Director
8,043   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Timothy P. Walbert
Chairman, President and CEO; Director
241,750   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
52,570   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Paul W. Hoelscher
EVP, CFO
66,822   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Barry J. Moze
EVP, Chief Admin. Officer
64,959   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Michael A. DesJardin
EVP, Technical Operations
53,734   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Miles W. McHugh
Sr VP & Princ. Acctg Officer
18,289   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Andy Pasternak
EVP and Chief Business Officer
48,839   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Elizabeth H.Z. Thompson
EVP, Research & Development
13,999   Derivative/Non-derivative trans. at $0 per share. 0
01/05/2022 Timothy P. Walbert
Chairman, President and CEO; Director
152,896   Award at $0 per share. 0
01/05/2022 Jeffrey W. Sherman
EVP and Chief Medical Officer
32,301   Award at $0 per share. 0
01/05/2022 Paul W. Hoelscher
EVP, CFO
47,375   Award at $0 per share. 0
01/05/2022 Barry J. Moze
EVP, Chief Admin. Officer
47,375   Award at $0 per share. 0
01/05/2022 Michael A. DesJardin
EVP, Technical Operations
32,301   Award at $0 per share. 0
12/31/2021 Timothy P. Walbert
Chairman, President and CEO; Director
7,522   Disposition at $108.55 per share. 816,513
12/31/2021 Timothy P. Walbert
Chairman, President and CEO; Director
67,478   Disposition at $108.02 per share. 7,288,973
12/31/2021 Timothy P. Walbert
Chairman, President and CEO; Director
25,000   Derivative/Non-derivative trans. at $22.14 per share. 553,500
12/28/2021 Paul W. Hoelscher
EVP, CFO
8,575   Disposition at $110 per share. 943,250
12/28/2021 Paul W. Hoelscher
EVP, CFO
8,575   Derivative/Non-derivative trans. at $15.96 per share. 136,857
12/13/2021 Jeffrey W. Sherman
EVP and Chief Medical Officer
50   Gift at $0 per share. 0
12/07/2021 Andy Pasternak
EVP and Chief Business Officer
1,525   Disposition at $100 per share. 152,500
12/03/2021 Paul W. Hoelscher
EVP, CFO
1,049   Gift at $0 per share. 0
12/01/2021 Miles W. McHugh
Sr VP & Princ. Acctg Officer
79,484   Disposition at $106.62 per share. 8,474,584
12/01/2021 Miles W. McHugh
Sr VP & Princ. Acctg Officer
79,484   Derivative/Non-derivative trans. at $22.14 per share. 1,759,775
/news/latest/company/us/hznp

MarketWatch News on HZNP

  1. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    7:32 a.m. May 21, 2021

    - Barron's Online

  2. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  3. Horizon to pay $53/share for each Viela share outstanding, a 53% premium

    7:03 a.m. Feb. 1, 2021

    - Tomi Kilgore

  4. Horizon Therapeutics to buy Viela Bio in a deal valued at $3.05 bln

    7:02 a.m. Feb. 1, 2021

    - Tomi Kilgore

  5. Cannabis Use Is on the Rise. Where to Invest Now.

    6:05 a.m. Oct. 12, 2020

    - Barron's Online

  6. Horizon Therapeutics started at overweight with $110 stock price target at J.P. Morgan

    6:54 a.m. Sept. 9, 2020

    - Tomi Kilgore

  7. Horizon's stock jumps on FDA adcomm support for eye drug

    8:40 a.m. Dec. 16, 2019

    - Jaimy Lee

  8. Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease

    7:01 a.m. Dec. 13, 2019

    - Ciara Linnane

  9. Horizon Therapeutics shares halted premarket for news pending

    6:56 a.m. Dec. 13, 2019

    - Ciara Linnane

  10. Four stocks that are nearing key breakouts

    2:23 p.m. Oct. 16, 2019

    - Harry Boxer

  11. Horizon Therapeutics upgraded to outperform from market perform at BMO Capital

    12:41 p.m. Aug. 14, 2019

    - Tomi Kilgore

  12. Loading more headlines...
/news/nonmarketwatch/company/us/hznp

Other News on HZNP

  1. Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion

    11:48 a.m. Jan. 11, 2022

    - Zacks.com

  2. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  3. White-Collar Employee Salaries Start to Swell

    5:30 a.m. Dec. 26, 2021

    - Lauren Weber

  4. Nation’s January Goal: Stay Open, Despite Omicron

    11:01 a.m. Dec. 22, 2021

    - Chip Cutter

  5. 4 Stocks Growing Free Cash Flow Fast

    11:38 a.m. Dec. 15, 2021

    - GuruFocus.com

  6. IBB And XBI: 4 Reasons To Buy Biotech Stocks Ahead Of 2022

    8:33 a.m. Dec. 6, 2021

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Horizon Therapeutics Plc

Connaught House

1 Burlington Road

1st Floor

Dublin, Dublin 4

Phone

353 17722100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$2.20B

Net Income

$389.80M

2020 Sales Growth

69.3%

Employees

1,395

/news/pressrelease/company/us/hznp

Press Releases on HZNP

  1. ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

    7:45 a.m. Jan. 11, 2022

    - PR Newswire - PRF

  2. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/202561856/composite MSTR-17.84%
  • /zigman2/quotes/205315244/composite DHT-4.09%
X
Powered by StockTwits
Link to MarketWatch's Slice.